Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Mar 31, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed SE between 2005 and 2019 who have been treated at intensive care units (ICUs) of the University Hospital of Basel
- Exclusion Criteria:
- • Patients with repetitive epileptic seizures not qualifying for SE or RSE
- • Patients with documented refusal of the general in-house consent
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Raoul Sutter, PD Dr. med
Principal Investigator
Universitätsspital Basel / Intensivmedizin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials